| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pelvic Organ Prolapse | 25 | 2024 | 162 | 8.020 |
Why?
|
| Gynecologic Surgical Procedures | 22 | 2024 | 157 | 5.660 |
Why?
|
| Hysterectomy | 12 | 2024 | 156 | 3.230 |
Why?
|
| Skin Neoplasms | 13 | 2014 | 598 | 2.740 |
Why?
|
| Urinary Incontinence | 13 | 2023 | 214 | 2.600 |
Why?
|
| Urinary Tract | 4 | 2022 | 34 | 2.400 |
Why?
|
| Vagina | 13 | 2024 | 177 | 2.180 |
Why?
|
| Gynecology | 8 | 2023 | 130 | 2.060 |
Why?
|
| Urologic Surgical Procedures | 9 | 2021 | 149 | 2.060 |
Why?
|
| Carcinoma, Squamous Cell | 15 | 2014 | 1098 | 1.870 |
Why?
|
| Microbiota | 5 | 2024 | 409 | 1.870 |
Why?
|
| Pelvic Floor Disorders | 8 | 2023 | 56 | 1.740 |
Why?
|
| Neovascularization, Pathologic | 16 | 2014 | 354 | 1.650 |
Why?
|
| Minimally Invasive Surgical Procedures | 3 | 2024 | 258 | 1.540 |
Why?
|
| Robotic Surgical Procedures | 6 | 2024 | 319 | 1.520 |
Why?
|
| Postoperative Complications | 16 | 2024 | 2314 | 1.480 |
Why?
|
| Stromal Cells | 6 | 2014 | 151 | 1.420 |
Why?
|
| Patient Satisfaction | 10 | 2023 | 460 | 1.320 |
Why?
|
| Electric Stimulation Therapy | 4 | 2022 | 47 | 1.300 |
Why?
|
| Urinary Bladder, Overactive | 4 | 2023 | 90 | 1.290 |
Why?
|
| Female | 85 | 2024 | 46602 | 1.250 |
Why?
|
| Obstetrics | 6 | 2022 | 123 | 1.240 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 4 | 2012 | 111 | 1.130 |
Why?
|
| Lower Urinary Tract Symptoms | 7 | 2024 | 70 | 1.040 |
Why?
|
| Humans | 110 | 2024 | 89985 | 1.020 |
Why?
|
| Laparoscopy | 9 | 2024 | 780 | 1.010 |
Why?
|
| Vascular Endothelial Growth Factor A | 7 | 2014 | 405 | 1.000 |
Why?
|
| Keratinocytes | 7 | 2014 | 146 | 0.980 |
Why?
|
| Anal Canal | 7 | 2021 | 88 | 0.980 |
Why?
|
| Urinary Incontinence, Stress | 8 | 2022 | 198 | 0.960 |
Why?
|
| Suburethral Slings | 7 | 2021 | 77 | 0.950 |
Why?
|
| Urinary Incontinence, Urge | 6 | 2022 | 47 | 0.930 |
Why?
|
| Pelvic Floor | 4 | 2021 | 85 | 0.890 |
Why?
|
| Middle Aged | 46 | 2024 | 26159 | 0.870 |
Why?
|
| Matrix Metalloproteinase 13 | 3 | 2014 | 7 | 0.830 |
Why?
|
| Postoperative Care | 2 | 2021 | 231 | 0.820 |
Why?
|
| Urology | 3 | 2021 | 121 | 0.800 |
Why?
|
| Aged | 34 | 2024 | 19262 | 0.790 |
Why?
|
| Ureter | 2 | 2020 | 95 | 0.780 |
Why?
|
| Surveys and Questionnaires | 12 | 2022 | 2657 | 0.780 |
Why?
|
| Neoplasm Invasiveness | 12 | 2014 | 569 | 0.760 |
Why?
|
| Pain Measurement | 4 | 2021 | 332 | 0.760 |
Why?
|
| Sexual Dysfunction, Physiological | 2 | 2020 | 69 | 0.760 |
Why?
|
| Convalescence | 1 | 2021 | 12 | 0.740 |
Why?
|
| Interleukin-6 | 2 | 2014 | 264 | 0.740 |
Why?
|
| Intraoperative Complications | 3 | 2020 | 185 | 0.730 |
Why?
|
| Narcotics | 1 | 2021 | 71 | 0.720 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 3 | 2006 | 166 | 0.710 |
Why?
|
| Research Personnel | 1 | 2021 | 72 | 0.700 |
Why?
|
| Quality of Life | 8 | 2022 | 1682 | 0.700 |
Why?
|
| Macrophages | 3 | 2012 | 582 | 0.670 |
Why?
|
| Mentors | 1 | 2021 | 90 | 0.670 |
Why?
|
| Pain, Postoperative | 2 | 2021 | 256 | 0.670 |
Why?
|
| Sex Characteristics | 1 | 2022 | 328 | 0.670 |
Why?
|
| Urologic Diseases | 1 | 2019 | 44 | 0.650 |
Why?
|
| Health Status Indicators | 1 | 2019 | 103 | 0.650 |
Why?
|
| Mice, Nude | 17 | 2014 | 816 | 0.640 |
Why?
|
| Sexual Behavior | 2 | 2018 | 313 | 0.620 |
Why?
|
| Retrospective Studies | 25 | 2024 | 9216 | 0.620 |
Why?
|
| Sexual Dysfunctions, Psychological | 1 | 2018 | 35 | 0.600 |
Why?
|
| Treatment Outcome | 17 | 2024 | 8277 | 0.590 |
Why?
|
| Personal Satisfaction | 1 | 2018 | 64 | 0.590 |
Why?
|
| Fibroblasts | 6 | 2014 | 759 | 0.590 |
Why?
|
| Surgeons | 1 | 2022 | 249 | 0.580 |
Why?
|
| Exercise | 1 | 2021 | 328 | 0.580 |
Why?
|
| Surgical Wound Infection | 1 | 2019 | 202 | 0.580 |
Why?
|
| Adult | 35 | 2024 | 26827 | 0.570 |
Why?
|
| Postoperative Period | 5 | 2024 | 301 | 0.570 |
Why?
|
| RNA, Ribosomal, 16S | 3 | 2022 | 251 | 0.550 |
Why?
|
| Directive Counseling | 1 | 2017 | 35 | 0.550 |
Why?
|
| Matrix Metalloproteinase 9 | 3 | 2012 | 86 | 0.550 |
Why?
|
| Biomedical Research | 1 | 2021 | 405 | 0.530 |
Why?
|
| Matrix Metalloproteinase 2 | 2 | 2014 | 48 | 0.530 |
Why?
|
| Cell Communication | 3 | 2014 | 200 | 0.520 |
Why?
|
| Matrix Metalloproteinases, Secreted | 2 | 2012 | 2 | 0.510 |
Why?
|
| Matrix Metalloproteinase Inhibitors | 3 | 2014 | 13 | 0.510 |
Why?
|
| Lacerations | 3 | 2021 | 27 | 0.500 |
Why?
|
| Sacrum | 4 | 2024 | 44 | 0.490 |
Why?
|
| Fecal Incontinence | 6 | 2021 | 58 | 0.490 |
Why?
|
| Surgical Mesh | 3 | 2022 | 124 | 0.470 |
Why?
|
| Rectocele | 1 | 2014 | 7 | 0.470 |
Why?
|
| Inflammation | 2 | 2013 | 981 | 0.470 |
Why?
|
| Urodynamics | 3 | 2024 | 123 | 0.450 |
Why?
|
| Estrogens | 1 | 2014 | 200 | 0.430 |
Why?
|
| Proto-Oncogene Proteins c-sis | 3 | 2010 | 29 | 0.430 |
Why?
|
| Mice | 22 | 2014 | 11858 | 0.430 |
Why?
|
| Physicians | 1 | 2021 | 692 | 0.430 |
Why?
|
| Sexism | 3 | 2023 | 54 | 0.420 |
Why?
|
| Cross-Sectional Studies | 9 | 2022 | 1731 | 0.410 |
Why?
|
| Operative Time | 4 | 2024 | 147 | 0.400 |
Why?
|
| Time Factors | 9 | 2024 | 5358 | 0.400 |
Why?
|
| Tissue Culture Techniques | 1 | 2012 | 82 | 0.400 |
Why?
|
| Urinary Bladder | 6 | 2024 | 248 | 0.390 |
Why?
|
| Animals | 26 | 2023 | 27536 | 0.390 |
Why?
|
| Cystoscopy | 3 | 2020 | 38 | 0.390 |
Why?
|
| Disease Progression | 8 | 2021 | 1469 | 0.380 |
Why?
|
| Prospective Studies | 13 | 2024 | 4329 | 0.380 |
Why?
|
| Carcinogenesis | 1 | 2013 | 216 | 0.380 |
Why?
|
| Pulmonary Embolism | 1 | 2014 | 232 | 0.380 |
Why?
|
| Venous Thrombosis | 1 | 2014 | 256 | 0.380 |
Why?
|
| Cell Culture Techniques | 1 | 2012 | 194 | 0.380 |
Why?
|
| Platelet-Derived Growth Factor | 2 | 2010 | 66 | 0.360 |
Why?
|
| Matrix Metalloproteinases | 2 | 2009 | 29 | 0.360 |
Why?
|
| Length of Stay | 3 | 2024 | 749 | 0.360 |
Why?
|
| Urogenital Abnormalities | 2 | 2020 | 20 | 0.350 |
Why?
|
| Hysterectomy, Vaginal | 2 | 2020 | 15 | 0.350 |
Why?
|
| Cell Transformation, Neoplastic | 4 | 2006 | 450 | 0.350 |
Why?
|
| Botulinum Toxins, Type A | 2 | 2021 | 50 | 0.350 |
Why?
|
| Cell Movement | 6 | 2014 | 787 | 0.350 |
Why?
|
| United States | 11 | 2024 | 7114 | 0.350 |
Why?
|
| Delivery, Obstetric | 4 | 2021 | 120 | 0.350 |
Why?
|
| Neoplasm Transplantation | 5 | 2014 | 397 | 0.340 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2012 | 1284 | 0.340 |
Why?
|
| Interleukin-4 | 3 | 2017 | 129 | 0.330 |
Why?
|
| Hospitalization | 1 | 2015 | 888 | 0.320 |
Why?
|
| Reoperation | 2 | 2021 | 604 | 0.310 |
Why?
|
| Cell Division | 3 | 2006 | 692 | 0.300 |
Why?
|
| Colonic Neoplasms | 1 | 2012 | 572 | 0.300 |
Why?
|
| Cells, Cultured | 9 | 2014 | 2887 | 0.300 |
Why?
|
| Recovery of Function | 2 | 2021 | 298 | 0.300 |
Why?
|
| Severity of Illness Index | 6 | 2019 | 1862 | 0.300 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 3 | 2014 | 68 | 0.290 |
Why?
|
| Extracellular Matrix | 2 | 2014 | 245 | 0.290 |
Why?
|
| Cell Line, Tumor | 9 | 2012 | 2588 | 0.290 |
Why?
|
| Double-Blind Method | 3 | 2021 | 1714 | 0.280 |
Why?
|
| Growth Substances | 1 | 2006 | 79 | 0.270 |
Why?
|
| Transfection | 4 | 2012 | 909 | 0.270 |
Why?
|
| Cytokines | 1 | 2010 | 811 | 0.270 |
Why?
|
| Aged, 80 and over | 8 | 2021 | 6785 | 0.270 |
Why?
|
| Urination | 3 | 2024 | 38 | 0.270 |
Why?
|
| Quality Improvement | 2 | 2021 | 457 | 0.270 |
Why?
|
| Urethra | 3 | 2021 | 116 | 0.260 |
Why?
|
| Blood Loss, Surgical | 2 | 2024 | 116 | 0.260 |
Why?
|
| Clinical Competence | 2 | 2022 | 797 | 0.250 |
Why?
|
| Adenocarcinoma | 1 | 2012 | 1185 | 0.250 |
Why?
|
| Cell Proliferation | 6 | 2012 | 1670 | 0.250 |
Why?
|
| Neoplasms, Experimental | 2 | 2007 | 269 | 0.250 |
Why?
|
| Time-to-Treatment | 3 | 2021 | 124 | 0.240 |
Why?
|
| Pandemics | 2 | 2021 | 778 | 0.240 |
Why?
|
| Postpartum Period | 4 | 2021 | 153 | 0.240 |
Why?
|
| Rheology | 1 | 2024 | 41 | 0.240 |
Why?
|
| Urogenital System | 1 | 2024 | 10 | 0.240 |
Why?
|
| Personnel Selection | 2 | 2023 | 60 | 0.230 |
Why?
|
| Risk Factors | 7 | 2021 | 5562 | 0.230 |
Why?
|
| Internship and Residency | 3 | 2023 | 1063 | 0.230 |
Why?
|
| Obstetric Labor Complications | 2 | 2021 | 34 | 0.230 |
Why?
|
| Neoplasms | 5 | 2008 | 3067 | 0.230 |
Why?
|
| Meningioma | 1 | 2004 | 62 | 0.220 |
Why?
|
| Meningeal Neoplasms | 1 | 2004 | 66 | 0.220 |
Why?
|
| 46, XX Disorders of Sex Development | 1 | 2023 | 10 | 0.220 |
Why?
|
| Uterine Prolapse | 2 | 2014 | 82 | 0.220 |
Why?
|
| Suture Techniques | 2 | 2024 | 144 | 0.220 |
Why?
|
| Social Determinants of Health | 1 | 2024 | 103 | 0.220 |
Why?
|
| Congenital Abnormalities | 1 | 2023 | 64 | 0.220 |
Why?
|
| Gardnerella | 1 | 2022 | 2 | 0.210 |
Why?
|
| Fellowships and Scholarships | 2 | 2023 | 126 | 0.210 |
Why?
|
| Coculture Techniques | 2 | 2014 | 176 | 0.210 |
Why?
|
| Preoperative Period | 2 | 2020 | 94 | 0.210 |
Why?
|
| Social Support | 1 | 2024 | 216 | 0.210 |
Why?
|
| Life Change Events | 1 | 2022 | 48 | 0.200 |
Why?
|
| Carcinoma | 1 | 2006 | 438 | 0.200 |
Why?
|
| Self Care | 2 | 2024 | 166 | 0.200 |
Why?
|
| Clinical Decision-Making | 2 | 2024 | 281 | 0.200 |
Why?
|
| Epithelial Cells | 1 | 2006 | 689 | 0.200 |
Why?
|
| Databases, Factual | 3 | 2020 | 866 | 0.200 |
Why?
|
| Cohort Studies | 7 | 2024 | 2886 | 0.200 |
Why?
|
| Urination Disorders | 2 | 2019 | 50 | 0.200 |
Why?
|
| In Situ Hybridization | 2 | 2014 | 313 | 0.200 |
Why?
|
| Feasibility Studies | 1 | 2024 | 785 | 0.200 |
Why?
|
| Correspondence as Topic | 1 | 2021 | 4 | 0.190 |
Why?
|
| Grooming | 1 | 2021 | 17 | 0.190 |
Why?
|
| Extraction, Obstetrical | 1 | 2021 | 7 | 0.190 |
Why?
|
| Mice, Inbred C57BL | 4 | 2014 | 3253 | 0.190 |
Why?
|
| Phenotype | 3 | 2006 | 2457 | 0.190 |
Why?
|
| Tumor Cells, Cultured | 5 | 2012 | 1048 | 0.190 |
Why?
|
| Interdisciplinary Placement | 1 | 2021 | 1 | 0.190 |
Why?
|
| Muscle, Striated | 1 | 2021 | 6 | 0.180 |
Why?
|
| Contraceptive Agents | 1 | 2021 | 20 | 0.180 |
Why?
|
| Urinary Bladder Fistula | 1 | 2020 | 4 | 0.180 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 3 | 2010 | 374 | 0.180 |
Why?
|
| Dyspareunia | 1 | 2021 | 22 | 0.180 |
Why?
|
| Urinary Tract Infections | 1 | 2021 | 76 | 0.180 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 6 | 2008 | 79 | 0.180 |
Why?
|
| Neuromuscular Agents | 1 | 2021 | 27 | 0.180 |
Why?
|
| Current Procedural Terminology | 1 | 2020 | 12 | 0.180 |
Why?
|
| Cell Adhesion | 2 | 2014 | 426 | 0.180 |
Why?
|
| Appointments and Schedules | 2 | 2023 | 54 | 0.180 |
Why?
|
| Pregnancy | 7 | 2021 | 3046 | 0.180 |
Why?
|
| Education | 1 | 2020 | 58 | 0.180 |
Why?
|
| Clinical Coding | 1 | 2020 | 24 | 0.180 |
Why?
|
| Goals | 1 | 2021 | 67 | 0.180 |
Why?
|
| Lumbosacral Plexus | 1 | 2020 | 9 | 0.180 |
Why?
|
| Watchful Waiting | 1 | 2021 | 66 | 0.180 |
Why?
|
| Glioblastoma | 4 | 2009 | 268 | 0.180 |
Why?
|
| Leadership | 1 | 2022 | 141 | 0.180 |
Why?
|
| Supine Position | 1 | 2020 | 30 | 0.170 |
Why?
|
| Integrin alphaVbeta3 | 3 | 2009 | 17 | 0.170 |
Why?
|
| Flow Cytometry | 2 | 2014 | 690 | 0.170 |
Why?
|
| Child Abuse | 1 | 2021 | 85 | 0.170 |
Why?
|
| Ureteral Obstruction | 1 | 2020 | 69 | 0.170 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2021 | 102 | 0.170 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2020 | 64 | 0.170 |
Why?
|
| Pelvic Pain | 1 | 2021 | 84 | 0.170 |
Why?
|
| Telemedicine | 1 | 2023 | 195 | 0.170 |
Why?
|
| Infertility, Female | 1 | 2020 | 96 | 0.170 |
Why?
|
| Specialties, Surgical | 1 | 2020 | 66 | 0.170 |
Why?
|
| Intermittent Urethral Catheterization | 1 | 2019 | 5 | 0.170 |
Why?
|
| Documentation | 1 | 2020 | 103 | 0.170 |
Why?
|
| Transplantation, Heterologous | 4 | 2009 | 368 | 0.170 |
Why?
|
| Racism | 1 | 2021 | 92 | 0.170 |
Why?
|
| Male | 15 | 2023 | 42690 | 0.170 |
Why?
|
| Implantable Neurostimulators | 1 | 2019 | 12 | 0.170 |
Why?
|
| Needs Assessment | 1 | 2020 | 161 | 0.170 |
Why?
|
| Abdomen | 1 | 2020 | 124 | 0.170 |
Why?
|
| Follow-Up Studies | 3 | 2021 | 3678 | 0.170 |
Why?
|
| Patient Positioning | 1 | 2020 | 65 | 0.170 |
Why?
|
| Pressure | 1 | 2020 | 167 | 0.160 |
Why?
|
| Iatrogenic Disease | 1 | 2019 | 70 | 0.160 |
Why?
|
| Pilot Projects | 1 | 2022 | 872 | 0.160 |
Why?
|
| Circumcision, Female | 1 | 2019 | 4 | 0.160 |
Why?
|
| RNA, Messenger | 4 | 2009 | 2026 | 0.160 |
Why?
|
| Head and Neck Neoplasms | 1 | 2006 | 1061 | 0.160 |
Why?
|
| Reproducibility of Results | 3 | 2024 | 2769 | 0.160 |
Why?
|
| Infection Control | 1 | 2020 | 124 | 0.160 |
Why?
|
| Electrodes, Implanted | 1 | 2020 | 185 | 0.160 |
Why?
|
| Asymptomatic Diseases | 1 | 2019 | 45 | 0.160 |
Why?
|
| Venous Thromboembolism | 1 | 2021 | 161 | 0.160 |
Why?
|
| Incidence | 2 | 2021 | 1604 | 0.160 |
Why?
|
| Patient Participation | 1 | 2021 | 226 | 0.160 |
Why?
|
| Orgasm | 1 | 2018 | 9 | 0.160 |
Why?
|
| Ethiopia | 1 | 2018 | 37 | 0.150 |
Why?
|
| Genital Neoplasms, Female | 1 | 2019 | 108 | 0.150 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2018 | 608 | 0.150 |
Why?
|
| Young Adult | 6 | 2024 | 6415 | 0.150 |
Why?
|
| Bacteria | 1 | 2022 | 486 | 0.150 |
Why?
|
| Surgical Procedures, Operative | 1 | 2020 | 206 | 0.150 |
Why?
|
| Self Report | 1 | 2019 | 297 | 0.150 |
Why?
|
| Wounds and Injuries | 1 | 2020 | 265 | 0.140 |
Why?
|
| Lactobacillus acidophilus | 1 | 2017 | 7 | 0.140 |
Why?
|
| Contrast Media | 3 | 2009 | 1084 | 0.140 |
Why?
|
| Chemokine CCL22 | 1 | 2017 | 8 | 0.140 |
Why?
|
| Oligopeptides | 2 | 2009 | 188 | 0.140 |
Why?
|
| Weight-Bearing | 1 | 2017 | 67 | 0.140 |
Why?
|
| Leiomyoma | 1 | 2021 | 204 | 0.140 |
Why?
|
| Logistic Models | 3 | 2021 | 1214 | 0.140 |
Why?
|
| Coitus | 1 | 2016 | 20 | 0.140 |
Why?
|
| Uterine Neoplasms | 1 | 2021 | 250 | 0.140 |
Why?
|
| Education, Medical, Graduate | 1 | 2020 | 403 | 0.140 |
Why?
|
| Patient Handoff | 1 | 2018 | 95 | 0.130 |
Why?
|
| Phylogeny | 1 | 2022 | 1198 | 0.130 |
Why?
|
| Stress, Psychological | 1 | 2019 | 322 | 0.130 |
Why?
|
| Cystitis, Interstitial | 1 | 2017 | 53 | 0.130 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2009 | 885 | 0.130 |
Why?
|
| Curriculum | 1 | 2020 | 573 | 0.130 |
Why?
|
| Activities of Daily Living | 1 | 2017 | 205 | 0.130 |
Why?
|
| Ultrasonography, Doppler | 2 | 2007 | 85 | 0.130 |
Why?
|
| Multivariate Analysis | 2 | 2016 | 983 | 0.120 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 319 | 0.120 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 305 | 0.120 |
Why?
|
| Endothelial Cells | 2 | 2009 | 464 | 0.120 |
Why?
|
| Anesthesia, General | 1 | 2016 | 116 | 0.120 |
Why?
|
| Hospitals, Low-Volume | 1 | 2015 | 19 | 0.120 |
Why?
|
| Referral and Consultation | 1 | 2018 | 345 | 0.120 |
Why?
|
| Hospitals, High-Volume | 1 | 2015 | 38 | 0.120 |
Why?
|
| Prosthesis Implantation | 1 | 2016 | 129 | 0.120 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2018 | 841 | 0.120 |
Why?
|
| Age Factors | 2 | 2018 | 1880 | 0.110 |
Why?
|
| Sex Factors | 3 | 2023 | 1075 | 0.110 |
Why?
|
| Culture Media, Conditioned | 1 | 2014 | 103 | 0.110 |
Why?
|
| Glioma | 2 | 2009 | 295 | 0.110 |
Why?
|
| Ambulatory Surgical Procedures | 1 | 2014 | 74 | 0.110 |
Why?
|
| Antibodies, Monoclonal | 5 | 2007 | 1396 | 0.110 |
Why?
|
| Estradiol | 1 | 2014 | 250 | 0.110 |
Why?
|
| Receptors, Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2012 | 7 | 0.110 |
Why?
|
| HT29 Cells | 1 | 2012 | 50 | 0.100 |
Why?
|
| Biomarkers | 1 | 2019 | 1778 | 0.100 |
Why?
|
| Adolescent | 5 | 2024 | 9345 | 0.100 |
Why?
|
| Mental Health | 2 | 2024 | 180 | 0.100 |
Why?
|
| Ferrosoferric Oxide | 2 | 2009 | 19 | 0.100 |
Why?
|
| Dextrans | 2 | 2009 | 79 | 0.100 |
Why?
|
| Sutures | 2 | 2024 | 57 | 0.100 |
Why?
|
| Macrophage Activation | 1 | 2012 | 49 | 0.100 |
Why?
|
| Cell Line, Transformed | 1 | 2012 | 154 | 0.100 |
Why?
|
| Magnetic Resonance Imaging | 5 | 2009 | 3477 | 0.100 |
Why?
|
| Chicago | 1 | 2016 | 1434 | 0.100 |
Why?
|
| Critical Care | 1 | 2015 | 384 | 0.090 |
Why?
|
| Immunoenzyme Techniques | 2 | 2009 | 303 | 0.090 |
Why?
|
| Immunity, Cellular | 1 | 2012 | 178 | 0.090 |
Why?
|
| Interleukin-10 | 1 | 2012 | 155 | 0.090 |
Why?
|
| Piperazines | 2 | 2010 | 283 | 0.090 |
Why?
|
| Patient Readmission | 1 | 2015 | 355 | 0.090 |
Why?
|
| Bone Marrow Cells | 1 | 2012 | 262 | 0.090 |
Why?
|
| Tumor Burden | 2 | 2009 | 310 | 0.090 |
Why?
|
| Urinary Retention | 2 | 2021 | 42 | 0.090 |
Why?
|
| Paracrine Communication | 2 | 2009 | 32 | 0.090 |
Why?
|
| STAT3 Transcription Factor | 1 | 2010 | 86 | 0.090 |
Why?
|
| Pyrimidines | 2 | 2010 | 371 | 0.090 |
Why?
|
| Pelvis | 2 | 2021 | 96 | 0.090 |
Why?
|
| Receptor, Platelet-Derived Growth Factor beta | 1 | 2009 | 26 | 0.090 |
Why?
|
| Poland | 2 | 2020 | 18 | 0.080 |
Why?
|
| Cathepsin B | 1 | 2009 | 12 | 0.080 |
Why?
|
| Base Sequence | 2 | 2010 | 2329 | 0.080 |
Why?
|
| DNA Primers | 1 | 2010 | 543 | 0.080 |
Why?
|
| Cathepsins | 1 | 2009 | 21 | 0.080 |
Why?
|
| Imatinib Mesylate | 1 | 2009 | 126 | 0.080 |
Why?
|
| Hepatocyte Growth Factor | 2 | 2006 | 84 | 0.080 |
Why?
|
| Blotting, Western | 1 | 2010 | 793 | 0.080 |
Why?
|
| Benzamides | 1 | 2009 | 234 | 0.080 |
Why?
|
| Endocytosis | 1 | 2009 | 180 | 0.080 |
Why?
|
| Emotions | 2 | 2023 | 354 | 0.080 |
Why?
|
| Xenograft Model Antitumor Assays | 5 | 2010 | 486 | 0.080 |
Why?
|
| Tumor Microenvironment | 1 | 2012 | 476 | 0.080 |
Why?
|
| Up-Regulation | 2 | 2009 | 726 | 0.070 |
Why?
|
| Child | 4 | 2023 | 7242 | 0.070 |
Why?
|
| Cell Line | 2 | 2009 | 2495 | 0.070 |
Why?
|
| Endothelium, Vascular | 1 | 2009 | 435 | 0.070 |
Why?
|
| Physical Fitness | 1 | 2007 | 50 | 0.070 |
Why?
|
| Endostatins | 1 | 2006 | 6 | 0.070 |
Why?
|
| Receptors, Platelet-Derived Growth Factor | 1 | 2006 | 17 | 0.070 |
Why?
|
| Immunohistochemistry | 3 | 2008 | 1801 | 0.070 |
Why?
|
| Depression | 2 | 2024 | 512 | 0.070 |
Why?
|
| Ferric Compounds | 1 | 2007 | 38 | 0.070 |
Why?
|
| RNA, Neoplasm | 1 | 2006 | 88 | 0.070 |
Why?
|
| Hyaluronic Acid | 1 | 2006 | 51 | 0.070 |
Why?
|
| Overweight | 1 | 2007 | 119 | 0.070 |
Why?
|
| Neoplasm Metastasis | 1 | 2010 | 1066 | 0.070 |
Why?
|
| Mesoderm | 1 | 2006 | 124 | 0.070 |
Why?
|
| Neoplasm Staging | 2 | 2009 | 2000 | 0.070 |
Why?
|
| Prevalence | 2 | 2021 | 1250 | 0.060 |
Why?
|
| Neovascularization, Physiologic | 1 | 2006 | 143 | 0.060 |
Why?
|
| Health Promotion | 1 | 2007 | 165 | 0.060 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2009 | 586 | 0.060 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2008 | 293 | 0.060 |
Why?
|
| Oxides | 1 | 2005 | 43 | 0.060 |
Why?
|
| Collagenases | 1 | 2005 | 41 | 0.060 |
Why?
|
| Granulocytes | 1 | 2004 | 38 | 0.060 |
Why?
|
| Iopamidol | 1 | 2004 | 10 | 0.060 |
Why?
|
| Iohexol | 1 | 2004 | 24 | 0.060 |
Why?
|
| Disease Models, Animal | 1 | 2012 | 2395 | 0.060 |
Why?
|
| Urine Specimen Collection | 1 | 2024 | 5 | 0.060 |
Why?
|
| Iron | 1 | 2005 | 168 | 0.060 |
Why?
|
| Mitotic Index | 1 | 2004 | 22 | 0.060 |
Why?
|
| Precancerous Conditions | 1 | 2006 | 201 | 0.060 |
Why?
|
| Needles | 1 | 2024 | 40 | 0.060 |
Why?
|
| Tomography, Spiral Computed | 1 | 2004 | 77 | 0.060 |
Why?
|
| Autocrine Communication | 1 | 2004 | 20 | 0.060 |
Why?
|
| Social Class | 1 | 2024 | 137 | 0.060 |
Why?
|
| Blood Vessels | 1 | 2004 | 94 | 0.060 |
Why?
|
| Specimen Handling | 1 | 2024 | 103 | 0.060 |
Why?
|
| Mullerian Ducts | 1 | 2023 | 18 | 0.060 |
Why?
|
| Actins | 1 | 2006 | 462 | 0.050 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2006 | 346 | 0.050 |
Why?
|
| Practice Guidelines as Topic | 2 | 2020 | 1055 | 0.050 |
Why?
|
| Pediatrics | 1 | 2007 | 361 | 0.050 |
Why?
|
| Equipment Design | 1 | 2024 | 422 | 0.050 |
Why?
|
| Observer Variation | 1 | 2024 | 614 | 0.050 |
Why?
|
| Constriction, Pathologic | 1 | 2023 | 222 | 0.050 |
Why?
|
| Pessaries | 1 | 2022 | 9 | 0.050 |
Why?
|
| Office Visits | 1 | 2023 | 50 | 0.050 |
Why?
|
| Tenascin | 1 | 2002 | 9 | 0.050 |
Why?
|
| Endopeptidases | 1 | 2002 | 118 | 0.050 |
Why?
|
| Swine | 1 | 2023 | 590 | 0.050 |
Why?
|
| Linguistics | 1 | 2021 | 12 | 0.050 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2005 | 603 | 0.050 |
Why?
|
| Remission, Spontaneous | 1 | 2021 | 52 | 0.050 |
Why?
|
| Administration, Intravesical | 1 | 2021 | 34 | 0.050 |
Why?
|
| Translations | 1 | 2020 | 5 | 0.050 |
Why?
|
| Epispadias | 1 | 2020 | 5 | 0.050 |
Why?
|
| Bladder Exstrophy | 1 | 2020 | 10 | 0.050 |
Why?
|
| Combined Modality Therapy | 2 | 2021 | 1704 | 0.050 |
Why?
|
| Adrenal Hyperplasia, Congenital | 1 | 2020 | 25 | 0.050 |
Why?
|
| Polydioxanone | 1 | 2020 | 4 | 0.050 |
Why?
|
| Spinal Dysraphism | 1 | 2020 | 19 | 0.040 |
Why?
|
| Fertility | 1 | 2021 | 116 | 0.040 |
Why?
|
| Surgical Oncology | 1 | 2020 | 28 | 0.040 |
Why?
|
| Electric Stimulation | 1 | 2021 | 365 | 0.040 |
Why?
|
| Menorrhagia | 1 | 2021 | 26 | 0.040 |
Why?
|
| Electromyography | 1 | 2021 | 195 | 0.040 |
Why?
|
| Patient Selection | 1 | 2024 | 682 | 0.040 |
Why?
|
| Organizational Innovation | 1 | 2020 | 43 | 0.040 |
Why?
|
| Polytetrafluoroethylene | 1 | 2020 | 74 | 0.040 |
Why?
|
| Organ Size | 1 | 2021 | 372 | 0.040 |
Why?
|
| Linear Models | 1 | 2021 | 422 | 0.040 |
Why?
|
| Electric Power Supplies | 1 | 2019 | 8 | 0.040 |
Why?
|
| Electronic Health Records | 1 | 2023 | 351 | 0.040 |
Why?
|
| Prostheses and Implants | 1 | 2020 | 125 | 0.040 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2021 | 195 | 0.040 |
Why?
|
| Nocturia | 1 | 2019 | 19 | 0.040 |
Why?
|
| Language | 1 | 2020 | 157 | 0.040 |
Why?
|
| Quality Indicators, Health Care | 1 | 2020 | 149 | 0.040 |
Why?
|
| Symptom Assessment | 1 | 2019 | 67 | 0.040 |
Why?
|
| Decision Making | 1 | 2024 | 671 | 0.040 |
Why?
|
| Wound Healing | 1 | 2021 | 361 | 0.040 |
Why?
|
| Child, Preschool | 2 | 2021 | 3773 | 0.040 |
Why?
|
| Cost-Benefit Analysis | 1 | 2020 | 467 | 0.040 |
Why?
|
| Recurrence | 1 | 2021 | 1145 | 0.040 |
Why?
|
| Magnetite Nanoparticles | 2 | 2009 | 27 | 0.040 |
Why?
|
| Decision Support Techniques | 1 | 2019 | 168 | 0.040 |
Why?
|
| Betacoronavirus | 1 | 2020 | 262 | 0.040 |
Why?
|
| Medicare | 1 | 2020 | 427 | 0.040 |
Why?
|
| Tertiary Care Centers | 1 | 2018 | 110 | 0.040 |
Why?
|
| Brain | 2 | 2023 | 2306 | 0.030 |
Why?
|
| Operating Rooms | 1 | 2018 | 125 | 0.030 |
Why?
|
| Urine | 1 | 2017 | 92 | 0.030 |
Why?
|
| Obstetrical Forceps | 1 | 2016 | 9 | 0.030 |
Why?
|
| Illinois | 1 | 2018 | 485 | 0.030 |
Why?
|
| Perineum | 1 | 2016 | 36 | 0.030 |
Why?
|
| Cell Differentiation | 1 | 2002 | 1533 | 0.030 |
Why?
|
| Brain Neoplasms | 1 | 2002 | 784 | 0.030 |
Why?
|
| Particle Size | 2 | 2007 | 126 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2005 | 2677 | 0.030 |
Why?
|
| Body Mass Index | 1 | 2018 | 776 | 0.030 |
Why?
|
| Pain | 1 | 2017 | 399 | 0.030 |
Why?
|
| Registries | 1 | 2018 | 808 | 0.030 |
Why?
|
| Perfusion | 2 | 2005 | 253 | 0.030 |
Why?
|
| Mutation | 1 | 2004 | 4169 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2017 | 1866 | 0.030 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-1 | 1 | 2010 | 18 | 0.020 |
Why?
|
| Organic Chemicals | 1 | 2010 | 34 | 0.020 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-2 | 1 | 2010 | 24 | 0.020 |
Why?
|
| Umbilical Veins | 1 | 2009 | 46 | 0.020 |
Why?
|
| Chemokine CXCL12 | 1 | 2009 | 38 | 0.020 |
Why?
|
| Protease Inhibitors | 1 | 2009 | 72 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2009 | 323 | 0.020 |
Why?
|
| Rats | 2 | 2005 | 4048 | 0.020 |
Why?
|
| Collagen | 1 | 2010 | 294 | 0.020 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2009 | 217 | 0.020 |
Why?
|
| Microtubules | 1 | 2008 | 123 | 0.020 |
Why?
|
| Silanes | 1 | 2007 | 1 | 0.020 |
Why?
|
| Propylamines | 1 | 2007 | 9 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2007 | 305 | 0.020 |
Why?
|
| Cell Survival | 1 | 2009 | 983 | 0.020 |
Why?
|
| Life Style | 1 | 2007 | 176 | 0.020 |
Why?
|
| Carcinoma, Lewis Lung | 1 | 2005 | 24 | 0.020 |
Why?
|
| Counseling | 1 | 2007 | 166 | 0.020 |
Why?
|
| Radiography, Abdominal | 1 | 2005 | 70 | 0.020 |
Why?
|
| Health Status | 1 | 2007 | 371 | 0.020 |
Why?
|
| Cell Growth Processes | 1 | 2005 | 85 | 0.020 |
Why?
|
| Ultrasonography | 1 | 2008 | 720 | 0.020 |
Why?
|
| Staining and Labeling | 1 | 2005 | 169 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2009 | 3024 | 0.010 |
Why?
|
| Histological Techniques | 1 | 2004 | 36 | 0.010 |
Why?
|
| Barium Sulfate | 1 | 2004 | 43 | 0.010 |
Why?
|
| Chemotherapy, Cancer, Regional Perfusion | 1 | 2003 | 18 | 0.010 |
Why?
|
| Bone and Bones | 1 | 2005 | 271 | 0.010 |
Why?
|
| Fibroblast Growth Factor 2 | 1 | 2004 | 57 | 0.010 |
Why?
|
| Pulmonary Fibrosis | 1 | 2005 | 138 | 0.010 |
Why?
|
| Radiography, Thoracic | 1 | 2005 | 324 | 0.010 |
Why?
|
| Extracellular Matrix Proteins | 1 | 2004 | 127 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2007 | 2018 | 0.010 |
Why?
|
| Ovarian Neoplasms | 1 | 2009 | 772 | 0.010 |
Why?
|
| Stem Cells | 1 | 2005 | 376 | 0.010 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 1 | 2004 | 95 | 0.010 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2005 | 1237 | 0.010 |
Why?
|
| Heart | 1 | 2005 | 578 | 0.010 |
Why?
|
| Kidney | 1 | 2005 | 1148 | 0.010 |
Why?
|
| Lung | 1 | 2005 | 1292 | 0.010 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2002 | 1355 | 0.010 |
Why?
|